TetraLogic CEO: Obamacare May Impact Drug Industry in Long Term
NEW YORK | By Ana Fuentes | In some countries like India or Saudi Arabia pharmaceutical companies face a crucial year. What about the U.S.? Will the Obamacare, for example, impact them in any way? Kevin Buchi, CEO of TetraLogic, a mid-sized pharma that just went public and is focused on small molecule drugs against cancer, among others, tells us about the investors’ fears.